The Prolaris® test provides an analysis of your individual tumor aggressiveness as well as a clinically validated prostate cancer-specific mortality risk. Two patients with the same PSA and Gleason scores may have a very different estimate of mortality risk when their Prolaris Score is included in their evaluation. Since cancer is the uncontrolled rapid growth of abnormal cells, an aggressive prostate tumor carries the potential risk of growing and spreading rapidly to other parts of your body.
The Prolaris Score is calculated by directly measuring the biology of the tumor and how fast the cells in your tumor or dividing. Since you have already had a biopsy which determined that you have prostate cancer, that tissue sample can also be used to determine your Prolaris Score. And, because every individual’s prostate cancer is different, the result of your Prolaris test is unique to you.
Patient Sample Report:
This page contains an interactive patient sample report. Hover your cursor over different parts of the form to learn what each particular section means.
1. Cuzick J, Berney DM, Fisher G, et al; Transatlantic Prostate Group. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 2012;106(6):1095-1099.
2. Data on file. Salt Lake City, UT: Myriad Genetic Laboratories, Inc.
3. Lin DW, et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urologic Oncology: Seminars and original investigations. 2018.